An eventful quarter sets the agenda for an intense 2022

Regulatory press release 2022-05-06

First Quarter 2022 (January 1 – March 31), Group

Net sales amounted to SEK 0 thousand (0)
Loss before tax amounted to SEK -18,934 thousand (-13,912)
Earnings per share before dilution amounted to SEK -0.92 (-0.73)
Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971)
Cash flow from investing activities amounted to SEK -47,541 thousand (-25,188)
Cash and cash equivalents at the end of the period amount-ed to SEK 196,212 thousand (292,265)

Amounts in parentheses refer to the year-earlier period.

Significant events during the quarter

In January, the FDA announced that the application for market approval of Dasynoc had been accepted for a full review.
In February, the company announced that it had hired Anna-Karin Ekberg as Global Head of Marketing and Sales. Anna-Karin took office on March 15, 2022 and is now part of the company’s management group.
In February, it was announced that Bristol Myers Squibb had filed a lawsuit against Xspray Pharma in the US claiming pa-tent infringement in relation to the submission of Xspray Pharma’s 505(b)(2) New Drug Application to the FDA.

“Xspray Pharma is in an intense period, with a focus on building up the company, commercialization, the project portfolio, and production capacity. It is intensive, rewarding work for all of us,” says Per Andersson, CEO.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com